Nam Dang, M.D.

Nam H Dang, M.D., Ph.D.

(352) 265-0725

Current patients:
Log in to MyUFHealth

Publications

Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report.
BMC gastroenterology
2021

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
Biomarker Research
2021

Secondary Gamma-Delta T-Cell Lymphoma Not Otherwise Specified (NOS) From Chronic Immunosuppression.
Cureus
2021

Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes.
Leukemia & lymphoma
2021

IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
Cell death & disease
2021

Diffuse Large B-Cell Lymphoma Presenting as an Unusual Paraneoplastic Neurologic Syndrome Affecting the Central and Peripheral Nervous Systems.
Cureus
2021

CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions.
Cureus
2021

A Multi-Center Retrospective Analysis Examining the Effect of Dipeptidyl Peptidase-4 Inhibitors on Progression-Free Survival in Patients With Prostate Cancer.
Cureus
2021

Successful Surgical Removal of the Largest Known Spleen.
Case reports in surgery
2020

Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder.
Cureus
2020

Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.
Pediatric transplantation
2020

Intravascular Large B-Cell Lymphoma Presenting as Acute Axonal Polyneuropathy: A Case Report and Literature Review.
Journal of investigative medicine high impact case reports
2020

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer.
Frontiers in oncology
2020

Bilateral pseudohypopyon causing white eyes in a patient with lymphoma.
Lancet (London, England)
2020

Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy.
Modern rheumatology
2019

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Blood
2019

Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study.
Cancer medicine
2019

Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
PloS one
2019

DPP8 is a novel therapeutic target for multiple myeloma.
Scientific reports
2019

Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis.
mAbs
2019

Biological Effects of IL-26 on T Cell-Mediated Skin Inflammation, Including Psoriasis.
The Journal of investigative dermatology
2019

A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers.
Molecular and clinical oncology
2019

Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22.
Biochemical and biophysical research communications
2018

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
British journal of haematology
2018

A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target.
Frontiers in bioscience (Landmark edition)
2018

A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target.
Frontiers in bioscience (Landmark edition)
2018

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients.
Experimental hematology & oncology
2017

Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
Journal of drug assessment
2017

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
British journal of cancer
2017

A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus.
Journal of dermatological science
2017

Role of IL-26+CD26+CD4 T Cells in Pulmonary Chronic Graft-Versus-Host Disease and Treatment with Caveolin-1-Ig Fc Conjugate.
Critical reviews in immunology
2016

Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
ACS chemical biology
2016

Low Grade Lymphoma Mimicking Metastatic Urothelial Carcinoma: When Do We Need Further Histologic Staging?
Case reports in oncological medicine
2016

Inhibition of VEGF-dependent angiogenesis by the anti-CD82 monoclonal antibody 4F9 through regulation of lipid raft microdomains.
Biochemical and biophysical research communications
2016

Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis.
Leukemia & lymphoma
2016

A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia.
Case reports in oncological medicine
2016

The role of Cas-L/NEDD9 as a regulator of collagen-induced arthritis in a murine model.
Biochemical and biophysical research communications
2015

Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes.
Journal of immunology (Baltimore, Md. : 1950)
2015

Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
Leukemia & lymphoma
2015

New primary malignancy masquerading as metastatic prostate adenocarcinoma.
Case reports in oncological medicine
2015

Modulation of immunological responses and amelioration of collagen-induced arthritis by the novel roxithromycin derivative 5-I.
Modern rheumatology
2015

Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission.
Case reports in oncological medicine
2015

Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum.
Journal of clinical laboratory analysis
2015

CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway.
Journal of immunology (Baltimore, Md. : 1950)
2015

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.
British journal of cancer
2014

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
British journal of haematology
2014

Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
International journal of radiation oncology, biology, physics
2014

Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.
Diagnostic pathology
2014

CD9 negatively regulates CD26 expression and inhibits CD26-mediated enhancement of invasive potential of malignant mesothelioma cells.
PloS one
2014

CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
Biochemical and biophysical research communications
2014

ALK1 as a novel therapeutic target for CD30⁺ T-anaplastic large cell lymphoma.
Journal of the National Cancer Institute
2014

The role of monoclonal antibodies in the treatment of lymphomas.
Expert opinion on biological therapy
2013

Survey of the University of Florida Hematology/Oncology Fellows On Perceived Skills of Independent Management of Oncologic Pain, Chemotherapy-Related Nausea and Vomiting, and End-Of-Life Discussions
Journal of Clinical Oncology
2013

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013

Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody.
British journal of haematology
2013

Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
Diabetes research and clinical practice
2013

Phase 2 Study of Consolidative Involved-Node Proton Therapy in Patients With Hodgkin Lymphoma: Early Outcomes
International Journal of Radiation Oncology Biology Physics
2013

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
British journal of haematology
2013

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.
Journal of virology
2013

CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production.
Immunology
2013

CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion.
BMC cancer
2013

Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma.
Case reports in hematology
2012

Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
2012

Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
2012

Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma.
International journal of radiation oncology, biology, physics
2012

Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
International journal of radiation oncology, biology, physics
2012

Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.
Biochemical and biophysical research communications
2012

Characterization of Cancer Stem Cell Properties of Cd24 and Cd26-Positive Human Malignant Mesothelioma Cells (Vol 419, Pg 529, 2012)
Biochemical and Biophysical Research Communications
2012

CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
Clinical cancer research : an official journal of the American Association for Cancer Research
2012

Anti-Tumor Activity of Low Dose Ocaratuzumab in Previously Treated Follicular Lymphoma Patients With Low-Affinity Cd16 Polymorphisms
Blood
2012

Advantages of Proton Therapy in the Management of Primary Mediastinal B-Cell Lymphoma (Pmbcl)
British Journal of Haematology
2012

Reducing the Dose To the Cardiac Chambers, Valves, and Vessels With Proton Therapy Compared With 3D-Crt and Imrt in Patients With Mediastinal Hodgkin Lymphoma
International Journal of Radiation Oncology Biology Physics
2011

Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines.
BMC cancer
2011

Dipeptidyl peptidase in autoimmune pathophysiology.
Advances in clinical chemistry
2011

Combination therapy for renal cell cancer: what are possible options?
Oncology
2011

A New Derivative of Roxithromycin Modulates Immunological Responses and Ameliorates Collagen-Induced Arthritis
Arthritis and Rheumatism
2011

Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines.
Biochemical and biophysical research communications
2010

Aqueous extract of Carica papaya leaves exhibits anti-tumor activity and immunomodulatory effects.
Journal of ethnopharmacology
2010

Anti-Cd22 Immunoconjugate Inotuzumab Ozogamicin (Cmc-544) + Rituximab: Clinical Activity in Patients With Relapsed/Refractory Follicular Or `Aggressive' Lymphoma
Haematologica
2010

SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration.
Biochemical and biophysical research communications
2009

CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells.
Biochemical and biophysical research communications
2009

CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells.
Biochemical and biophysical research communications
2009

CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion.
British journal of cancer
2009

Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4+T cells.
Biochemical and biophysical research communications
2009

Anti-Cd22 Immunoconjugate Inotuzumab Ozogamicin (Cmc-544) + Rituximab: Clinical Activity Including Survival in Patients With Recurrent/Refractory Follicular Or `Aggressive' Lymphoma
Blood
2009

The role of CD26/dipeptidyl peptidase IV in cancer.
Frontiers in bioscience : a journal and virtual library
2008

Role of CD26/dipeptidyl peptidase IV in human T cell activation and function.
Frontiers in bioscience : a journal and virtual library
2008

Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.
Trends in immunology
2008

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
Cancer research
2008

De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.
American journal of hematology
2008

Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood.
Clinical & developmental immunology
2008

Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma.
Biochemical and biophysical research communications
2007

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
British journal of haematology
2007

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
British journal of haematology
2007

Knockdown of XAB2 enhances all-trans retinoic acid-induced cellular differentiation in all-trans retinoic acid-sensitive and -resistant cancer cells.
Cancer research
2007

Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research
2007

Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
Cancer investigation
2007

Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1.
The Journal of biological chemistry
2007

CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
Mini reviews in medicinal chemistry
2007

T-cell activation via CD26 and caveolin-1 in rheumatoid synovium.
Modern rheumatology
2006

Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
Clinical cancer research : an official journal of the American Association for Cancer Research
2006

Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma.
Leukemia & lymphoma
2005

Roxithromycin specifically inhibits development of collagen induced arthritis and production of proinflammatory cytokines by human T cells and macrophages.
The Journal of rheumatology
2005

Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.
Cancer research
2005

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Cancer
2005

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005

Nedd9 protein, a Cas-L homologue, is upregulated after transient global ischemia in rats: possible involvement of Nedd9 in the differentiation of neurons after ischemia.
Stroke
2005

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005

HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L).
Oncogene
2005

CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299.
Cancer research
2005

CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells.
Molecular and cellular biology
2005

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2004

Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
Clinical cancer research : an official journal of the American Association for Cancer Research
2004

Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
Clinical journal of oncology nursing
2004

CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy.
Current drug targets. Immune, endocrine and metabolic disorders
2004

CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.
Proceedings of the National Academy of Sciences of the United States of America
2004

Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation.
Blood
2004

T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition.
British journal of haematology
2003

SS-A/Ro52, an autoantigen involved in CD28-mediated IL-2 production.
Journal of immunology (Baltimore, Md. : 1950)
2003

Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Oncology reports
2003

CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).
International journal of oncology
2003

CD26: a key molecule in immune regulation and autoimmune diseases.
Modern rheumatology
2003

Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.
Cellular immunology
2002

G1/S cell cycle arrest provoked in human T cells by antibody to CD26.
Immunology
2002

Research Interests

  • Dr. Dang's primary research effort emphasizes the development of novel treatment strategies for patients with lymphoma/CLL through the identification of new targets and the utilization of novel targeted therapies. To achieve this aim, he has conducted multiple clinical trials and is active in laboratory research with the goal of translating laboratory findings to the clinical setting for the ultimate benefit of the patient.

Active Research Studies